CTRI Number |
CTRI/2021/07/034527 [Registered on: 02/07/2021] Trial Registered Prospectively |
Last Modified On: |
30/06/2021 |
Post Graduate Thesis |
Yes |
Type of Trial |
Interventional |
Type of Study
|
Medical Device Surgical/Anesthesia |
Study Design |
Other |
Public Title of Study
|
Comparison of two different types of second generation LMAs in ear surgeries under TIVA |
Scientific Title of Study
|
Comparison of ease of insertion of two different types of second generation Laryngeal mask airways in aural surgeries under total intravenous anaesthesia |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Nupur Aggarwal |
Designation |
Pg 1st year Anaesthesia |
Affiliation |
School of medical sciences & research |
Address |
Department of Anaesthesiology School of Medical Sciences & Research Sharda University plot no 32,34, knowledge park 3, greater noida Gautam Buddha Nagar UTTAR PRADESH 201310 India |
Phone |
9654145106 |
Fax |
|
Email |
NUPUR.AGGARWAL@SHARDA.AC.IN |
|
Details of Contact Person Scientific Query
|
Name |
Dr Aarti Srivastava |
Designation |
Professor & Head of Department |
Affiliation |
School of medical sciences & research |
Address |
Department of Anaesthesiology
School of Medical Sciences & Research
Sharda University plot no 32,34, knowledge park 3, greater noida Gautam Buddha Nagar UTTAR PRADESH 201310 India |
Phone |
9811966766 |
Fax |
|
Email |
aarti.srivastava@sharda.ac.in |
|
Details of Contact Person Public Query
|
Name |
Dr Nupur Aggarwal |
Designation |
Pg 1st year Anaesthesia |
Affiliation |
School of medical sciences & research |
Address |
Department of Anaesthesiology
School of Medical Sciences & Research
Sharda University plot no 32,34, knowledge park 3, greater noida Gautam Buddha Nagar UTTAR PRADESH 201310 India |
Phone |
9654145106 |
Fax |
|
Email |
NUPUR.AGGARWAL@SHARDA.AC.IN |
|
Source of Monetary or Material Support
|
|
Primary Sponsor
|
Name |
Sharda hospital |
Address |
plot no 32, 34, knowledge park 3, greater noida, uttar pradesh- 201310 |
Type of Sponsor |
Private medical college |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Nupur Aggarwal |
Sharda hospital School of Medical Sciences & Research |
Department of Anaesthesiology, 2ND floor, B block Gautam Buddha Nagar UTTAR PRADESH |
09654145106
NUPUR.AGGARWAL@SHARDA.AC.IN |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Institutional Ethics Committee |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: H60-H95||Diseases of the ear and mastoid process, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Intervention |
i gel |
Second generation laryngeal mask airway( iGel) will be used to see- 1.Ease of insertion of the device
2.Insertion time- time between picking up the device and obtaining an effective airway
3.Attempts of insertion - three insertion attempts will be allowed before a failure of insertion is recorded.
Estimated time required for insertion of Igel is less than 45 seconds
|
Comparator Agent |
Proseal |
Second generation laryngeal mask airway( Proseal) will be used to see- 1.Ease of insertion of the device
2.Insertion time- time between picking up the device and obtaining an effective airway
3.Attempts of insertion - three insertion attempts will be allowed before a failure of insertion is recorded.
Estimated time required for insertion of Proseal is less than 60 seconds |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
45.00 Year(s) |
Gender |
Both |
Details |
1. ASA grade 1 & 2
2. Age 18-45 years
3. Patients scheduled for elective ear surgery with either I-gel or PLMA as airway device
|
|
ExclusionCriteria |
Details |
1. Patients with respiratory tract infection
2. Difficult airway (mouth opening <2cm, Mallampati class 4, limited neck extension, history of previous difficult intubation)
3. Known pulmonary and cardiovascular diseases
4. Risk of aspiration (full stomach, hiatus hernia, GERD)
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
Blinding/Masking
|
Participant Blinded |
Primary Outcome
|
Outcome |
TimePoints |
To compare ease of insertion and time taken for insertion of I gel v/s Proseal LMA. |
5 minutes |
|
Secondary Outcome
|
Outcome |
TimePoints |
a) To record the hemodynamic changes.
b) To check for postoperative sore throat
c) To check for postoperative nausea and vomiting.
|
1 minute before induction (baseline), just before LMA insertion, 5 minute after LMA insertion and 10 minute after LMA insertion
Patients will be observed for 1 hour after extubation in post- operative care unit. |
|
Target Sample Size
|
Total Sample Size="70" Sample Size from India="70"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
05/07/2021 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
Inhalational anaesthetic agents have remained the main stay in the conduct of anaesthesia. This is primarily because of their ability to produce surgical anaesthesia without the need of hepatic or renal metabolism for their elimination. However, many side effects of inhalational agents have been noticed like sensitization of myocardium by halothane and nephrotoxicity of methoxyflurane and operation theatre pollution. In addition, nitrous oxide which is used as a carrier gas with inhalational agents, can cause ozone layer depletion. To overcome these side effects of inhalational anaesthetic agents and nitrous oxide; an alternative technique was thought of. One such alternative technique is total intravenous anaesthesia (TIVA) where in there is total avoidance of nitrous oxide and inhalational anaesthetic agent and operative anaesthetic depth is maintained by continuous infusion of intravenous anaesthetic agent. Advantages of TIVA are1 1. Simplicity of technique and readily acceptance by patients. 2. Produces high quality anaesthetic condition 3. Minimal cardiovascular depression. 4. Avoidance of deleterious effect of volatile anaesthetics eg., hepatotoxicity 5. Speedy and complete recovery. 6. Avoids malignant hyperthermia. 7. Reduction in theatre pollution 8. Avoids distention of air-filled spaces within patient’s body, which is due to nitrous oxide. 9. Avoids postoperative diffusion hypoxemia 10. Decreases the incidence of PONV Propofol is currently the most suitable anaesthetic agent for total intravenous anaesthesia (TIVA); it allows for rapid changes in anaesthetic depth and a rapid, clear-headed recovery. Also, low context sensitive half-time 2 makes it theoretically the best available agent for long procedures under TIVA. Furthermore, propofol attenuates airway reflexes to the extent that the laryngeal mask airway (LMA) may be positioned easily without neuromuscular block 3 The Laryngeal Mask Airway (LMA) is a supraglottic airway device designed to maintain a clear airway, which sits outside of and creates a seal around the larynx. Compared with the face mask, the LMA allows for a more "handsfree approach" to airway management 4. In difficult airway management, LMA can bypass obstruction at supraglottic level and allow rescue oxygenation and ventilation, provided that mouth opening is sufficient 5. The LMA-ProSeal is a second generation supraglottic airway device with modified cuff and drainage tube, designed for better seal with both the respiratory and gastrointestinal tracts, not compromising the access to the alimentary tract. 6,7,8 The I-gel airway is a new supraglottic airway device with a non-inflatable cuff, composed of soft gel like, transparent thermoplastic elastomer. It is designed to achieve a mirror impression of pharyngeal and laryngeal structures and to provide a peri laryngeal seal without cuff inflation. A drain tube is placed lateral to the airway tube, which allows insertion of gastric tube.9 It has the potential advantages of easier insertion, minimal risk of tissue compression, stability after insertion and an inbuilt bite block.10 Patients undergoing surgery under general anesthesia require an adequate level of hypnosis to protect them from stress of awareness and recall of traumatic interventions. Conventionally, the hypnotic state is assessed by observing changes in the respiratory and cardiovascular system. However, in recent times, the hypnotic state is assessed by monitoring the electrical activity of the brain which directly indicates the depth of anesthesia. This has been made possible by the introduction of newer and more sophisticated delivery system for total intravenous anesthesia (TIVA) and the Bispectral index monitor, which allows a computed analysis of real time EEG to assess the depth of anesthesia continuously. |